Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.
Are you healthy? Do you have pancreatic cancer, pancreatitis or pancreatic cysts? In early testing, Texas researchers successfully used four blood biomarkers that aided in early-stage diagnosis to help tell the difference.
Evidence is mounting that circulating tumor cells in the bloodstream, also known as CTCs, are a viable cancer biomarker tool. A team in Germany produced new evidence that their presence, or absence, may be an effective way to measure the survival chance of patients with early breast cancer.
Wednesday night's big round of ASCO news highlighted a few key memes with major implications for cancer drug development and everyone who works in the field. Overall, there were no big surprises in the news. And that's news in itself.
California genetic testing startup Counsyl is launching BRCA and other predictive diagnostic tests. Crucially, $28 million in new Series D Financing will help kick all of this into high gear.
A team of Ohio researchers has affirmed the viability of a new biomarker that could enable earlier diagnosis of esophageal cancer, along with a noninvasive test that screens for it.
Biocept Laboratories' modest debut on the public markets in early February preceded a stock decline of more than 50% over the last few months. The week of April 28, however, Biocept's stock climbed more than 21% through Thursday after execs disclosed a promising new biomarker development service targeted to pharmaceutical companies.
Veracyte scored a major partnership deal with a large medical/diagnostic center that will help expand the reach of its signature thyroid cancer diagnostic technology throughout Brazil.
As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.
MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.